OMS721 for Patients with IgAN
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Breve descripción
This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN.
Médico del ensayo/Coordinador del estudio
Kien Nguyen
Correo electrónico Número de teléfono (206) 676-0886Nombre del patrocinador
Omeros Corporation
Nombre del fármaco del estudio
OMS721
Matrícula estimada
430
Fecha estimada de finalización
April 2023
OMS721 for Patients with IgAN
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Breve descripción
This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN.
El ensayo es para personas con
IgA Nephropathy
Objetivo del estudio
To determine if OMS721 reduces proteinuria in patients with IgAN.
Qué implica para el paciente?
Patients will be involved with the trial for about 2 years, and will take either the study medication or the placebo.
Sobre el medicamento o la intervención
MASP-2, is a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system.